Cervical screening in HPV-vaccinated populations

References

• Zur Hausen H. Viruses in human cancers. Curr Sci 2001;81:523–7
   Web of Science ®Google Scholar
• Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342–50
   PubMed Web of Science ®Google Scholar
• The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915–27
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301–14
   PubMed Web of Science ®Google Scholar
• Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine 2012;30(Suppl 5):F157–67
   PubMed Web of Science ®Google Scholar
• Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health 2014;2:70237–32
   Web of Science ®Google Scholar
• Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365:1576–85
   PubMed Web of Science ®Google Scholar
• Bogaards JA, Wallinga J, Brakenhoff RH, Meijer CJ, Berkhof J. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ 2015;350:h2016
   PubMed Web of Science ®Google Scholar
• Canfell K. Who should be vaccinated against HPV? BMJ 2015;350:h2244
   PubMedGoogle Scholar
• Lin A, Ong KJ, Hobbelen P, et al. Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men. Clin Infect Dis 2017;64:580–8
   PubMed Web of Science ®Google Scholar
• Drolet M, Benard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015;15:565–80
   PubMed Web of Science ®Google Scholar
• Gertig DM, Brotherton JML, Saville AM. Measuring human papillomavirus (HPV) vaccination coverage and the role of the national HPV vaccination program register, Australia. Sex Health 2011;8:171–8
   PubMed Web of Science ®Google Scholar
• Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012;206:1645–51
   PubMed Web of Science ®Google Scholar
• Tabrizi SN, Brotherton JM, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 2014;14:958–66
   PubMed Web of Science ®Google Scholar
• Smith MA, Liu B, McIntyre P, Menzies R, Dey A, Canfell K. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis 2015;211:91–9
   PubMed Web of Science ®Google Scholar
• Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013;346:f2032
   PubMed Web of Science ®Google Scholar
• Ali H, McManus H, O'Connor CC, et al. Human papillomavirus vaccination and genital warts in young indigenous Australians: national sentinel surveillance data. Med J Aust 2017;206:204–9
   PubMed Web of Science ®Google Scholar
• Ali H, Guy RJ, Wand H, et al. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis 2013;13:140
   PubMed Web of Science ®Google Scholar
• Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377:2085–92
   PubMed Web of Science ®Google Scholar
• Australian Institute of Health and Welfare. Cervical screening in Australia 2014–2015. Cancer series no. 105. Cat. no. CAN 104. Canberra: AIHW, 2017
   Google Scholar
• Joura EA, Giuliano AR, Iversen O-E, et al. A 9-Valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372:711–23
   PubMed Web of Science ®Google Scholar
• Simms KT, Laprise J-F, Smith MA, et al. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis. Lancet Public Health 2016;1:e66–75
   PubMedGoogle Scholar
• Brisson M, Laprise J-F, Chesson HW, et al. Health and economic impact of switching from a 4-valent to a 9-valent hpv vaccination program in the United States. J Natl Cancer Inst 2016;108:djv282.
   PubMedGoogle Scholar
• Laprise J-F, Markowitz LE, Chesson HW, Drolet M, Brisson M. Comparing 2- and 3-dose 9-valent HPV vaccine schedules in the US: a cost-effectiveness analysis. J Infect Dis 2016;214:685–8
   PubMed Web of Science ®Google Scholar
• Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis 2017;17:1293–302
   PubMed Web of Science ®Google Scholar
• Iversen O, Miranda M, Ulied A, et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA 2016;316:2411–21
   PubMed Web of Science ®Google Scholar
• Simonella L, Canfell K. The impact of a two- versus three-yearly cervical screening interval recommendation on cervical cancer incidence and mortality: an analysis of trends in Australia, New Zealand, and England. Cancer Causes Control 2013;24:1727–36
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention, Volume 10: Cervix Cancer Screening. Chapters 5–8: Effectiveness of screening in populations; Summary; Evaluation; Recommendations; Glossary. 2005, 201; 43, 93–8
   Google Scholar
• Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012;30(Suppl 5):F88–99
   PubMed Web of Science ®Google Scholar
• Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754
   PubMed Web of Science ®Google Scholar
• Burger EA, Kim JJ, Sy S, Castle PE. Age of acquiring causal human papillomavirus (HPV) infections: leveraging simulation models to explore the natural history of HPV-induced cervical cancer. Clin Infect Dis 2017;65:893–9
   PubMed Web of Science ®Google Scholar
• Schiffman M, Kinney WK, Cheung LC, et al. Relative performance of HPV and cytology components of cotesting in cervical screening. J Natl Cancer Inst 2017. doi: 10.1093/jnci/djx225. [Epub ahead of print].
   Google Scholar
• Isidean SD, Mayrand MH, Ramanakumar AV, et al. Human papillomavirus testing versus cytology in primary cervical cancer screening: end-of-study and extended follow-up results from the Canadian cervical cancer screening trial. Int J Cancer 2016;139:2456–66
   PubMed Web of Science ®Google Scholar
• Ogilvie GS, Krajden M, van Niekerk D, et al. HPV for cervical cancer screening (HPV FOCAL): complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer. Int J Cancer 2017;140:440–8
   PubMed Web of Science ®Google Scholar
• Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012;13:78–88
   PubMed Web of Science ®Google Scholar
• Dijkstra MG, van Zummeren M, Rozendaal L, et al. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. BMJ 2016;355:i4924
   PubMedGoogle Scholar
• Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:249–57
   PubMed Web of Science ®Google Scholar
• Kitchener HC, Canfell K, Gilham C, et al. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess 2014;18:1–196
   Web of Science ®Google Scholar
• Leinonen MK, Nieminen P, Lonnberg S, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ 2012;345:e7789
   PubMed Web of Science ®Google Scholar
• Elfstrom KM, Smelov V, Johansson AL, et al. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ 2014;348:g130
   PubMed Web of Science ®Google Scholar
• Wright TC, Jr., Stoler MH, Sharma A, Zhang G, Behrens C, Wright TL. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV + cytology-negative results. Am J Clin Pathol 2011;136:578–86
   PubMed Web of Science ®Google Scholar
• Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC, Jr, Cuzick J. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol 2013;208:e1–11
   PubMed Web of Science ®Google Scholar
• Canfell K, Caruana M, Gebski V, et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: results of the Compass pilot randomised trial. PLoS Med 2017;14:e1002388
   PubMed Web of Science ®Google Scholar
• Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095–101
   PubMed Web of Science ®Google Scholar
• Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524–32
   PubMed Web of Science ®Google Scholar
• Smith M, Canfell K. Impact of the Australian national cervical screening program in women of different ages. Med J Aust 2016;205:359–64
   PubMed Web of Science ®Google Scholar
• Smith MA, Canfell K. Projected impact of HPV vaccination and primary HPV screening on cervical adenocarcinoma: example from Australia. Papillomavirus Res 2017;3:134–41
   PubMed Web of Science ®Google Scholar
• Lew JB, Simms K, Smith M, Lewis H, Neal H, Canfell K. Effectiveness modelling and economic evaluation of primary HPV screening for cervical cancer prevention in New Zealand. PLoS One 2016;11:e0151619
   PubMed Web of Science ®Google Scholar
• Lew JB, Simms KT, Smith MA, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the national cervical screening program. Lancet Public Health 2017;2:e96–107
   PubMed Web of Science ®Google Scholar
• Smith MA, Gertig D, Hall M, et al. Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use. BMC Health Serv Res 2016;16:147
   PubMed Web of Science ®Google Scholar
• Hall MT, Simms KT, Lew J-B, Smith MA, Saville M, Canfell K. Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: example from Australia. PLoS One 2018;13:e0185332.
   PubMed Web of Science ®Google Scholar
• Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006;367:489–98
   PubMed Web of Science ®Google Scholar
• Kyrgiou M, Athanasiou A, Paraskevaidi M, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ 2016;354:i3633
   PubMed Web of Science ®Google Scholar
• Bruinsma FJ, Quinn MA. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. BJOG 2011;118:1031–41
   PubMed Web of Science ®Google Scholar
• Castanon A, Brocklehurst P, Evans H, et al. Risk of preterm birth after treatment for cervical intraepithelial neoplasia among women attending colposcopy in England: retrospective-prospective cohort study. BMJ 2012;345:e5174
   PubMedGoogle Scholar
• Lawton B, Howe AS, Turner N, et al. Association of prior HPV vaccination with reduced preterm birth: apopulation based study. Vaccine 2018;36:134–40
   PubMed Web of Science ®Google Scholar
• Sasieni P, Castanon A. Dramatic increase in cervical cancer registrations in young women in 2009 in England unlikely to be due to the new policy not to screen women aged 20-24. J Med Screen 2012;19:127–32
   PubMed Web of Science ®Google Scholar
• Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009;124:516–20
   PubMed Web of Science ®Google Scholar
• Simms KT, Hall M, Smith MA, et al. Optimal management strategies for primary HPV testing for cervical screening: cost-effectiveness evaluation for the national cervical screening program in Australia. PLoS One 2017;12:e0163509
   PubMed Web of Science ®Google Scholar
• Velentzis LS, Caruana M, Simms KT, et al. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country. Int J Cancer 2017;141:2410–22
   PubMed Web of Science ®Google Scholar
• Arbyn M, Verdoodt F, Snijders PJ, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 2014;15:172–83
   PubMed Web of Science ®Google Scholar
• Arbyn M, Castle PE. Offering self-sampling kits for HPV testing to reach women who do not attend in the regular cervical cancer screening program. Cancer Epidemiol Biomarkers Prev 2015;24:769–72
   PubMed Web of Science ®Google Scholar
• Hammond I, Canfell K, Saville M. A new era for cervical screening in Australia: watch this space! Aust N Z J Obstet Gynaecol 2017;57:499–501
   PubMed Web of Science ®Google Scholar
• Kim JJ, Burger EA, Sy S, Campos NG. Optimal cervical cancer screening in women vaccinated against human papillomavirus. JNCI J Natl Cancer Inst 2017;109:djw216
   Web of Science ®Google Scholar
• Simms KT, Smith MA, Lew JB, Kitchener HC, Castle PE, Canfell K. Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries. Int J Cancer 2016;139:2771–80
   PubMed Web of Science ®Google Scholar
• Wentzensen N, Arbyn M, Berkhof J, et al. Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. Int J Cancer 2017;140:2192–200
   PubMed Web of Science ®Google Scholar
• Saslow D, Solomon D, Lawson HW, et al. American cancer society, American society for colposcopy and cervical pathology, and American society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012;62:147–72
   PubMed Web of Science ®Google Scholar
• Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health 2016;4:e453–63
   PubMed Web of Science ®Google Scholar
• Jeronimo J, Castle PE, Temin S, et al. Secondary prevention of cervical cancer: ASCO resource-stratified clinical practice guideline. J Glob Oncol 2016;3:635–57
   PubMedGoogle Scholar